NC
HRMY icon

nVerses Capital’s Harmony Biosciences HRMY Stock Holding History

nVerses Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$36.2K – 1180
2024
Q2 		$36.2K Buy
+1,200
New +$36.1K 0.02% 653

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

nVerses Capital's HRMY Position: Q3 2024 in Review

nVerses Capital sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 1,200 shares — an estimated $36.2K sold.

nVerses Capital first reported a position in HRMY in Q2 2024 and held it in 1 quarter. The position peaked at $36.2K in Q2 2024. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

  • nVerses Capital reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 1,200 Harmony Biosciences shares in Q3 2024, an estimated $36.2K.
  • nVerses Capital first reported a position in Harmony Biosciences in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Harmony Biosciences position peaked at $36.2K in Q2 2024.
  • 233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.